Validation of prognostic impact of ADV score for resection of hepatocellular carcinoma: analysis using Korea Liver Cancer Registry Database

Gil-Chun Park¹, Shin Hwang¹, Yo-Han Park², Jin-Uk Choi³; Korean Liver Cancer Study Group

¹Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
²Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common malignancies and leading causes of cancer-related deaths worldwide. Hepatic resection (HR) is considered the first-line treatment in patients with preserved hepatic function; however, tumor recurrence occurs frequently and unpredictably after HR [1].

We previously demonstrated that the score derived from the multiplication of α-FP, des-γ-carboxyprothrombin (DCP or proteins induced by vitamin K antagonist or absence-II), and tumor volume (TV) (α-FP-DCP-TV score or simply ADV score)
is an integrated surrogate marker of postresection prognosis in solitary HCCs [2] and regarded as a quantifiable parameter reflecting tumor aggressiveness. It was also proven to be valid in patients with preoperatively treated HCCs [3].

The primary aim of this study was to estimate overall patient survival according to the preoperative and postoperative ADV scores, and the secondary aim was to determine the cutoff values of the ADV score for clinical application.

Treatment

Because the KLCR database does not provide information on the types and extents of HR, we simply described surgical resection of HCC as HR. Any treatment for postresection recurrence, including various locoregional treatments and systemic chemotherapy but excluding liver transplantation, was permissible. The general principles of treatment for recurrent HCC are described elsewhere [1,5].

ADV score

The values of $\alpha$-FP and DCP measured before HR were used. TV was calculated from the maximal tumor diameter under an assumption that the tumor is spherical. Multiplication of $\alpha$-FP (ng/mL), DCP (mAU/mL), and TV (mL) yields the ADV score, which is expressed in the logarithmic scale ($\log_{10}$ is simply presented as log) [2].

Postoperative TV was calculated by the information described at the pathology report, which was used for calculation of postoperative ADV score. In addition, the preoperative TV was calculated with the preoperative imaging findings, which was used for calculation of preoperative ADV score. If there were multiple HCC tumors, total TV was estimated as the TV of the largest tumor multiplied by the number of tumors. This TV weighted by the number of tumors is greater than the actual total TV, thus providing some weighted prognostic value from the number of tumors.

Data collection

Clinical parameters were collected, including age, sex, presence of chronic illness such as hypertension or diabetes mellitus, suspected etiologies of HCC such as viral hepatitis or heavy alcohol intake. Child-Pugh score and classification, model for end-stage liver disease score, Barcelona Clinic Liver Cancer (BCLC) stage at the time of HR, and TNM stage based on preoperative imaging and pathologic findings. Collected laboratory parameters included platelet, serum sodium, albumin, total bilirubin, creatinine, alanine aminotransferase, $\alpha$-FP, and DCP levels and international normalized ratio. Other clinical or laboratory parameters were excluded owing to insufficient data in the registry.

Statistical analysis

Numerical data are presented as means with standard deviations or as medians with ranges. Continuous variables were compared using Student t-test, and incidence variables were compared using the chi-square test or Fisher exact test.
Table 1. Clinical features of 1,390 patients who underwent hepatic resection for hepatocellular carcinoma according to tumor number and preoperative treatment

| Variable                        | Treatment-naive group | Preoperative-treated group | P-value |
|---------------------------------|-----------------------|---------------------------|---------|
|                                 | Single tumor (Group 1) | Multiple tumors (Group 2) |         |
|                                 | Single tumor (Group 3) | Multiple tumors (Group 4) |         |
| Patient number                  | 1,154                 | 170                       | 50      |
| Age (yr)                        | 56.8 ± 10.3           | 56.3 ± 11.0               | 0.47    |
| Sex, male:female                | 918:236               | 138:322                   | 0.62    |
| Diabetes mellitus               | 253                   | 39                        | 0.77    |
| Hypertension                    | 383                   | 60                        | 0.59    |
| Performance status              |                       |                           | 0.005   |
|                                | 840                   | 111                       | 28      |
|                                | 110                   | 25                        | 11      |
|                                | 6                     | 4                         | 2       |
|                                | Not available         | 198                       | 30      |
| Background liver disease        |                       |                           | 0.7     |
| HBV                             | 833                   | 123                       | 39      |
| HCV                             | 67                    | 15                        | 3       |
| ALD                             | 42                    | 1                         | 1       |
| Not available                   | 101                   | 17                        | 4       |
| Preoperative blood laboratory profiles |                  |                            |         |
| Albumin (g/dL)                  | 4.20 ± 0.46           | 4.10 ± 0.54               | 0.011   |
| Creatinine (mg/dL)              | 0.95 ± 0.73           | 0.87 ± 0.18               | 0.17    |
| Sodium (mmol/L)                 | 140.1 ± 3.9           | 139.6 ± 2.9               | 0.13    |
| ALT (IU/L)                      | 44.5 ± 61.2           | 50.9 ± 74.8               | 0.22    |
| Total bilirubin (mg/dL)         | 0.94 ± 1.08           | 0.95 ± 1.08               | 0.88    |
| Prothrombin time (INR)          | 1.13 ± 0.52           | 1.05 ± 0.10               | 0.69    |
| Platelet count (10^13/µL) at operation |                   |                           |         |
| Mean ± SD                       | 2,265.3 ± 13,737.4   | 3,562.8 ± 18,036.4        | 0.27    |
| Median                          | 19.6                  | 31.7                      |         |
| DCP (mAU/mL) at operation       |                       |                           |         |
| Mean ± SD                       | 1,610.1 ± 7,105.9     | 2,696.6 ± 9,237.9         | 0.075   |
| Median                          | 67                    | 177                       |         |
| ICG-R15 (%)                     | 11.9 ± 8.6            | 12.0 ± 8.0                | 0.98    |
| MELD score                      | 7.91 ± 2.19           | 7.59 ± 1.78               | 0.073   |
| CTP class                       | 0.22                  |                           |         |
| A                               | 1,120                 | 162                       | 49      |
| B                               | 34                    | 8                         | 1       |
| Preoperative imaging finding    |                       |                           |         |
| Maximal tumor diameter (cm)     | 4.05 ± 2.77           | 4.95 ± 3.45               | <0.001  |
| Mean tumor number (n)           | 1.09 ± 0.42           | 2.23 ± 1.11               | <0.001  |
| Total tumor volume (mL)         | 123.3 ± 399.3         | 508.2 ± 1,510.7           | <0.001  |
| Postoperative pathology finding |                       |                           |         |
| Maximal tumor diameter (cm)     | 4.18 ± 2.93           | 5.09 ± 3.63               | <0.001  |
| Mean tumor number (n)           | 1.00 ± 0.00           | 2.55 ± 1.01               | <0.001  |
| Total tumor volume (mL)         | 121.2 ± 350.8         | 669.1 ± 2,051.5           | <0.001  |
| ADV score (log10)               |                       |                           |         |
| Preoperative                    | 5.04 ± 2.07           | 5.99 ± 2.24               | <0.001  |
| Postoperative                   | 5.06 ± 2.11           | 6.10 ± 2.23               | <0.001  |
Overall survival period was computed from the day of HR until the most recent follow-up or death. Survival time and rate were estimated using the Kaplan-Meier method; differences between groups were assessed using the log-rank test. A P-value of <0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA).

RESULTS

Patient demographics

All 1,390 patients were classified according to the number of tumors and preoperative HCC treatment: their clinicopathologic features are summarized in Table 1.

The primary liver diseases were HBV infection in 1,007 patients (72.4%), HCV infection in 85 (6.1%), non-HBV non-HCV in 45 (3.2%), alcoholic liver disease in 125 (9.0%), and unknown (missing data) in 128 (9.2%).

In patients belonging to the single treatment-naive tumor group (group 1), the preoperative imaging diagnosis (n = 1,141) was a single tumor in 1,069 patients (93.7%), 2 tumors in 57 (5.0%), and 3 or more tumors in 15 (1.3%).

Patients in the preoperative-treated tumor groups (groups 3 and 4) underwent HR 164.7 ± 276.1 days (median, 54 days) after HCC treatment (radiofrequency ablation in 9, transarterial chemoembolization in 55, and transarterial radioembolization in 2).

During the follow-up period of 50.0 ± 24.9 months (median, 47.1 months), 315 of 1,390 patients (22.7%) died of HCC recurrence (n = 292, 92.7%) and other causes (n = 23, 7.3%). Overall patient survival curves of the 4 groups are presented in Fig. 1. The survival rate in group 1 was higher than that in the other 3 groups (P < 0.001); however, it was similar among the other 3 groups (P = 0.85).

Table 1. Continued.

| Variable | Treatment-naive group | Preoperative-treated group |
|----------|------------------------|---------------------------|
|          | Single tumor (Group 1) | Multiple tumors (Group 2) | P-value | Single tumor (Group 3) | Multiple tumors (Group 4) | P-value |
| BCLC stage | 0 | 78 | 2 | <0.001c | 2 | 1 | 0.94c |
|           | A | 726 | 56 | 21 | 6 | 3 | 4 |
|           | B | 70 | 51 | 6 | 3 | 0 | 0 |
|           | C | 187 | 44 | 16 | 6 | 2 | 0 |
|           | D | 0 | 0 | 0 | 0 | 0 | 0 |
| Not available | 93 | 17 | 5 | 2 | 3 | 3 | 3 |

Values are presented as mean ± standard deviation (SD) or number unless otherwise indicated.

DCP, des-γ-carboxyprothrombin; ADV, α-FP-DCP-tumor volume; ICG-R15, indocyanine green retention test at 15 minutes; MELD, model for end-stage liver disease; CTP, Child-Turcotte-Pugh; BCLC, Barcelona Clinic Liver Cancer.

a) Status 0 vs. status 1 + 2. b) HBV vs. others. c) Stage 0 + A vs. B + C + D. d) Stage I + II vs. III + IV-A + IV-B. e) Stage T1N0M0 + T2N0M0 vs. other stage.
Relationship between tumor size and tumor markers
In 1,154 patients belonging to the treatment-naive single tumor group (group 1), the association of $\alpha$-FP, DCP, and TV is presented in 2-dimensional scatter plots (Fig. 2). There was no significant correlation between the following combinations: $\alpha$-FP and DCP ($r^2 = 0.040, r = 0.200, P < 0.001$), TV and $\alpha$-FP ($r^2 = 0.016, r = 0.126, P < 0.001$), and TV and DCP ($r^2 = 0.037, r = 0.192, P < 0.001$). These results indicate that $\alpha$-FP, DCP, and TV are independent parameters.

Patient survival according to postoperative ADV score in patients with a single treatment-naive HCC
Of 1,154 patients with single treatment-naive tumor in group 1, 239 (20.7%) died during the mean follow-up period of 51.3 ± 24.8 months (median, 48.2 months). Their 1-, 2-, 3-, and 5-year overall survival rates were 94.9%, 90.6%, 86.0%, and 79.0%, respectively (Fig. 1).

The postoperative ADV scores were stratified by an interval of 1 log (10-fold). The distribution of ADV scores was as follows: <2 log in 26 (2.3%), 2–2.9 log in 129 (11.2%), 3–3.9 log in 248 (21.5%), 4–4.9 log in 243 (21.1%), 5–5.9 log in 168 (14.6%), 6–6.9 log in 117 (10.1%), 7–7.9 log in 84 (7.3%), 8–8.9 log in 68 (5.9%), 9–9.9 log in 48 (4.2%), 10–10.9 log in 12 (1.0%), and ≥11 log in 11 patients (1.0%).

The overall patient survival rate in each group was closely correlated with the ADV score ($P < 0.001$), in which the 5-year
survival rates were 92.1% in ADV <2log, 91.9% in ADV 2–2.9log, 87.9% in ADV 3–3.9log, 83.0% in ADV 4–4.9log, 76.8% in ADV 5–5.9log, 74.3% in ADV 6–6.9log, 66.9% in ADV 7–7.9log, 59.6% in ADV 8–8.9log, 60.1% in ADV 9–9.9log, 38.9% in ADV 10–10.9log, and 37.4% in ADV ≥11log (Fig. 3A).

Through cluster analysis, the postoperative ADV scores were stratified as ADV ≤4.9log, ADV 5–6.9log, ADV 7–9.9log, and ADV ≥10log, showing great prognostic contrast (P < 0.001) (Fig. 3B).

**Patient survival according to postoperative ADV score in patients with multiple treatment-naive HCCs**

In 170 patients with multiple treatment-naive tumors in group 2, 56 (32.9%) died during the mean follow-up period of 43.0 ± 23.9 months (median, 40.8 months). Their 1-, 2-, 3-, and 5-year overall survival rates were 94.9%, 90.6%, 86.0%, and 79.0%, respectively (Fig. 1).

The overall patient survival rate in each group was crudely correlated with the postoperative ADV score (P < 0.001), in which their 5-year survival rates were 100% in ADV 2–2.9log (n = 5), 100% in ADV 3–3.9log (n = 17), 67.3% in ADV 4–4.9log (n = 35), 64.0% in ADV 5–5.9log (n = 41), 40.93% in ADV 6–6.9log

**Fig. 3.** Comparison of overall patient survival curves in group 1 patients. (A) Comparison according to the postoperative ADV scores of 1log intervals. (B) Comparison in 4 subgroups with cutoffs of 5log, 7log, and 10log. ADV score, α-FP-des-γ-carboxyprothrombin-tumor volume score.

**Fig. 4.** Comparison of overall patient survival curves in group 2 patients. (A) Comparison according to the postoperative ADV scores of 1log intervals. (B) Comparison in 4 subgroups with cutoffs of 5log, 7log, and 10log. ADV score, α-FP-des-γ-carboxyprothrombin-tumor volume score.
(n = 19), 66.0% in 7–7.9log (n = 21), 50.0% in ADV 8–8.9log (n = 12), 80.0% in ADV 9–9.9log (n = 5), 50.0% in ADV 10–10.9log (n = 5), and 25.0% in ADV ≥11log (n = 10) (Fig. 4A).

Through cluster analysis, the postoperative ADV scores were stratified as ADV ≤ 4.9log, ADV 5–6.9log, ADV 7–9.9log, and ADV ≥ 10log, showing a noticeable prognostic contrast (P = 0.001) (Fig. 4B).

Patient survival according to postoperative ADV score in patients with preoperative-treated HCCs

In 50 patients with a single preoperative-treated tumor in group 3, 15 (30.0%) died during the mean follow-up period of 48.5 ± 28.5 months (median, 44.1 months). Their 1-, 2-, 3-, and 5-year overall survival rates were 96.0%, 82.0%, 75.6%, and 63.9%, respectively (Fig. 1). The overall patient survival rate in each group was crudely correlated with the postoperative ADV score (P = 0.003) (Fig. 5A). Through cluster analysis, the postoperative ADV scores were stratified as ADV ≤ 4.9log, ADV 5–6.9log, ADV 7–9.9log, and ADV ≥ 10log, showing a significant prognostic contrast (P = 0.007) (Fig. 5B).

In 16 patients with multiple preoperative-treated tumors in group 4, 5 (31.3%) died during the mean follow-up period of 38.6 ± 20.0 months (median, 36.0 months). Their 1-, 2-, 3-, and 5-year overall survival rates were 81.3%, 75.0%, 75.0%, and 50.0%, respectively (Fig. 1). The overall patient survival rate in each group was crudely correlated with the postoperative ADV score (P = 0.017) (Fig. 5C). Through cluster analysis, the postoperative ADV scores were stratified as ADV ≤ 4.9log, ADV 5–6.9log, ADV 7–9.9log, and ADV ≥ 10log, showing a significant prognostic contrast (P = 0.031) (Fig. 5D).

Prediction of patient survival using the preoperative ADV score based on the preoperative finding in patients diagnosed as having single treatment-naive HCC

Of 1,106 patients diagnosed as having single treatment-naive tumor in the preoperative imaging study, 227 (20.5%) died during the mean follow-up period of 50.9 ± 24.5 months.

Fig. 5. Comparison of overall patient survival curves. (A, B) Comparison according to the postoperative ADV scores of 1log intervals and in 4 subgroups with cutoffs of 5log, 7log, and 10log in group 3 patients. (C, D) Comparison according to the postoperative ADV scores of 1log intervals and in 4 subgroups with cutoffs of 5log, 7log, and 10log in group 4 patients. ADV score, α-FP-des-γ-carboxyprothrombin-tumor volume score.
**Fig. 6.** Comparison of overall patient survival curves according to the preoperative ADV score based on preoperative findings. (A) Comparison according to the preoperative ADV scores of 1log intervals. (B) Comparison in 4 subgroups with cutoffs of 5log, 7log, and 10log. ADV score, α-FP-des-γ-carboxyprothrombin-tumor volume score.

**Fig. 7.** Comparison of overall patient survival curves according to the tumor staging system and postoperative ADV score in group 1 and 2 patients. (A) Comparison according to the TNM staging system. (B) After confining patients to TNM stages I and II: comparison of 4 subgroups with postoperative ADV cutoffs of 5log, 7log, and 10log in group 3 patients. (C) Comparison according to Barcelona Clinic Liver Cancer (BCLC) stage. (D) After confining patients to BCLC stage 0 and A: comparison of 4 subgroups with postoperative ADV cutoffs of 5log, 7log, and 10log in group 3 patients. ADV score, α-FP-des-γ-carboxyprothrombin-tumor volume score.
The preoperative ADV scores were stratified by an interval of 10 log (10-fold). The distribution of the ADV scores was as follows: <2 log in 20 (1.8%), 2–2.9 log in 133 (12.0%), 3–3.9 log in 238 (21.5%), 4–4.9 log in 250 (20.8%), 5–5.9 log in 176 (15.9%), 6–6.9 log in 102 (9.2%), 7–7.9 log in 83 (7.5%), 8–8.9 log in 64 (5.8%), 9–9.9 log in 36 (3.3%), 10–10.9 log in 14 (1.3%), and ≥11 log in 10 patients (0.9%).

The overall patient survival rate in each group was closely correlated with the preoperative ADV score (P < 0.001), in which the 5-year survival rates were 94.7% in ADV < 2 log, 92.1% in ADV 2–2.9 log, 87.9% in ADV 3–3.9 log, 83.4% in ADV 4–4.9 log, 74.9% in ADV 5–5.9 log, 75.4% in ADV 6–6.9 log, 63.3% in 7–7.9 log, 63.6% in ADV 8–8.9 log, 58.8% in ADV 9–9.9 log, 37.5% in ADV 10–10.9 log, and 42.0% in ADV ≥11 log (Fig. 6A).

Through cluster analysis, the preoperative ADV scores were stratified as ADV ≤ 4.9 log, ADV 5–6.9 log, ADV 7–9.9 log, and ADV ≥ 10 log, showing a high prognostic contrast (P < 0.001) (Fig. 6B).

Survival analysis with postoperative TNM stage and BCLC stage in patients diagnosed as having naive HCC

In 1,324 patients belonging to groups 1 and 2, survival analysis with the postoperative TNM stage showed a highly noticeable prognostic contrast (P < 0.001) (Fig. 7A). However, 1,072 of 1,324 patients (81.0%) had TNM stage I and II diseases; there was a relatively low prognostic difference between stages I and II (P = 0.034). When confining to the 1,058 patients belonging to TNM stages I and II, stratification with the postoperative ADV score increased the prognostic contrast (P < 0.001) (Fig. 7B).

In 1,324 patients belonging to groups 1 and 2, survival analysis with the BCLC stage also showed a highly noticeable prognostic contrast (P < 0.001) (Fig. 7C). However, 862 of 1,324 patients (65.1%) had BCLC stage 0 and A disease, and there was a marginal prognostic difference between stage 0 and A (P = 0.074). When confining to the 862 patients belonging to BCLC stage 0 and A, stratification with the postoperative ADV score increased the prognostic contrast (P < 0.001) (Fig. 7D).

DISCUSSION

It is difficult to predict postresection prognosis in patients with HCC because carcinogenesis and tumor biology in these patients are highly complex and heterogeneous. There are several clinically important individual predictors that can be used before HR (e.g., tumor size, tumor markers, and 18-fluoro-deoxyglucose PET findings) and after HR (microvascular invasion [MVI]), as well various tumor staging systems for HCC [5–11]. The HCC tumor size has been accepted for a long time as one of the most important prognostic factors [1,12,13]. The expression of tumor markers, such as α-FP and DCP, is highly variable in HCC, as this study shows. Thus, to enhance the prognostic impact of tumor markers, multiple tumor markers need to be integrated in a single score, such as the sum of the number of positive tumor markers or multiplication of α-FP and DCP with different cutoff values [14–18]. However, the prognostic impact of these tumor markers is still not sufficiently high. Some specific imaging findings of gadoxetic acid-enhanced MRI and 18-fluoro-deoxyglucose PET indicate poor prognosis, but their prognostic impact is still debated.

MVI has been considered one of the most important prognostic parameters; however, because it is a pathologic finding, it is difficult to predict the status of MVI before HR. Many studies have predicted MVI using imaging findings (liver dynamic CT, gadoxetic acid-enhanced MRI, and 18-fluoro-deoxyglucose PET), tumor markers (α-FP, DCP, and next-generation DCP), and their combination [14–24]. The ADV score was also used for predicting MVI in a previous study, in which the area under the receiver-operating characteristic curve was as high as 0.788 [2]. These preoperative diagnostic approaches resulted in a significant increase in the discriminatory power for predicting MVI; however, their role is limited in clinical practice.

To overcome the demerits of individual prognostic parameters, we developed the ADV score as an integrated surrogate marker for postresection prognosis in HCC and as a quantifiable parameter reflecting tumor aggressiveness [2]. ADV score-dependent prognostic stratification was validated in 1 single-center study and 1 multicenter study [3,4], in which the ADV score was highly correlated with the postresection prognosis. The present study also demonstrated that the ADV score was proportionally correlated with patient survival. Considering that 92.7% of mortality cases were directly associated with HCC recurrence in this study, the ADV score must be proportionally correlated with tumor recurrence, as shown in previous studies [2–4,25].

The ADV score was originally developed for patients with single treatment-naive HCC. To our knowledge, this is the first study to evaluate the prognostic impact of the ADV score in patients with multiple HCCs. Although the number of patients with multiple tumors was not large in this study, we believe that the ADV score is reliably correlated with the postresection prognosis. To apply the ADV score to multiple HCCs, the total TV was estimated as the TV of the largest tumor multiplied by the number of tumors. This calculation method results in a significantly larger total TV than the arithmetical summation of the TVs of individual tumors. We believe that the ADV score calculated using a TV weighted by the number of tumors can
We previously showed that anatomical HR is superior to nonanatomical HR in patients with an ADV score ≤ 4log for tumor recurrence and in patients with an ADV score ≤ 5log for patient survival regardless of preoperative treatment. Thus, even an HCC with a lower ADV score is eligible for aggressive surgical resection [3,4]. There are various tumor staging systems for HCC; each system has its unique merits and limitations. In groups 1 and 2 in this study, the TNM staging system showed a highly noticeable prognostic contrast; however, 81% of the patients belonged to stages I and II, and there was no prognostic difference between these 2 stages. Such a low power of discrepancy is less helpful in clinical practice. In contrast, additional application of the ADV score resulted in noticeable enhancement of prognostic contrast. This ADV score-derived enhancement was repeatedly seen in patients with BCLC stage 0 and A. We also showed that the ADV score combined with MVI, 18-fluoro-deoxyglucose PET findings, or gene signature test can enhance the prognostic predictive power of individual parameters [2,4,25]. These findings indicate that the ADV score can be an additional predictive parameter combined with various HCC staging systems or other individual risk factors.

This study has limitations of note. This is a retrospective single-country cohort study in a HBV-endemic area. It is necessary to validate the ADV score in other geographic regions before our results can be extended to patients with HCC of various causes. Another major limitation is the lack of recurrence analysis because detailed information on tumor recurrence is not obtainable from the KLCR database. However, the survival status of all patients was followed up completely together with the government-led Korea Central Cancer Registry.

In conclusion, this external validation study strongly suggests that both the preoperative and postoperative ADV scores are integrated surrogate markers for postresection prognosis in patients with HCC. We believe that the ADV score is primarily applicable to patients with a single treatment-naive HCC and can be expanded to those with multiple or preoperative-treated HCCs.

ACKNOWLEDGEMENTS

The database used in this study was provided by the Korean Liver Cancer Study Group and the Korea Central Cancer Registry, Ministry of Health and Welfare, Korea.

Fund/Grant Support

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT and Future Planning (Grant No. 2019039742 to Shin Hwang).
Conflict of Interest
No potential conflict of interest relevant to this article was reported.

ORCID ID
Gil-Chun Park: https://orcid.org/0000-0003-1631-3258
Shin Hwang: https://orcid.org/0000-0002-9045-2531
Yo-Han Park: https://orcid.org/0000-0002-2242-0968
Jin-Uk Choi: https://orcid.org/0000-0001-8078-0593

Author Contribution
Conceptualization: SH
Formal Analysis: GCP, SH, YHP
Investigation: SH, JUC, KLCSD
Methodology: SH, JUC, KLCSD
Project Administration: SH, KLCSD
Writing – Original Draft: SH
Writing – Review & Editing: SH, GCP

REFERENCES

1. Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, et al. The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg 2015;19:1281-90.
2. Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, Moon DB, et al. Multiplication of tumor volume by two tumor markers is a post-resection prognostic predictor for solitary hepatocellular carcinoma. J Gastrointest Surg 2016;20:1807-20.
3. Jung DH, Hwang S, Lee YJ, Kim KH, Song GW, Ahn CS, et al. Small hepatocellular carcinoma with low tumor marker expression benefits more from anatomical resection than tumors with aggressive biology. Ann Surg 2019;269:511-9.
4. Hwang S, Joh JW, Wang HJ, Kim DG, Kim KS, Suh KS, et al. Prognostic prediction models for resection of large hepatocellular carcinoma: a Korean multicenter study. World J Surg 2018;42:2579-91.
5. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75.
6. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005;7:35-41.
7. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010;116:3006-14.
8. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system. the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-15.
9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
10. Bruix J, Sherman M: American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
11. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014;146:1691-700.
12. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009;29:502-10.
13. Zhang H, Yuan SX, Dai SY, Zhang JM, Huang X, Lu CD, et al. Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion. World J Surg 2014;38:947-57.
14. Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, et al. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol 2015;21:4933-45.
15. Kiriyama S, Uchiyama K, Ueno M, Ozawa S, Hayami S, Tani M, et al. Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival. Ann Surg 2011;254:984-91.
16. Nakagawa S, Beppu T, Okabe H, Sakamoto K, Kuroki H, Mima K, et al. Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma. Hepatol Res 2014;44:964-74.
17. Suh SW, Lee KW, Lee JM, You T, Choi Y, Kim H, et al. Prediction of aggressiveness in early-stage hepatocellular carcinoma for selection of surgical resection. J Hepatol 2014;60:1219-24.
18. Kamiyama T, Yokoo H, Kakaisaka T, Orimoto T, Wakayama K, Kamachi H, et al. Multiplication of alpha-fetoprotein and protein induced by vitamin K absence-II is a powerful predictor of prognosis and recurrence in hepatocellular carcinoma patients after a hepatectomy. Hepatol Res 2015;45:E21-31.
19. Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sporoletti C, et al. Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology 2016;279:432-42.
20. Ahn SY, Lee JM, Joo I, Lee ES, Lee SJ, Cheon GJ, et al. Prediction of microvascular invasion of hepatocellular carcinoma. Radiology 2016;279:432-42.
carcinoma using gadoxetic acid-enhanced MR and (18)F-FDG PET/CT. Abdom Imaging 2015;40:843-51.
21. Chou CT, Chen BC, Lin WC, Ko CJ, Chen CB, Chen YL. Prediction of microvascular invasion of hepatocellular carcinoma: preoperative CT and histopathologic correlation. AJR Am J Roentgenol 2014; 203:W253-9.
22. Min JH, Kim YK, Lim S, Jeong WK, Choi D, Lee WJ. Prediction of microvascular invasion of hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging: impact of intra-tumoral fat detected on chemical-shift images. Eur J Radiol 2015;84:1036-43.
23. Shirabe K, Toshima T, Kimura K, Yamashita Y, Ikeda T, Ikegami T, et al. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int 2014;34:937-41.
24. Pote N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castéra L, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol 2015;62:848-54.
25. Ha SM, Hwang S, Park JY, Lee YJ, Kim KH, Song GW, et al. Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas. Ann Surg Treat Res 2018;95:303-11.
26. Kang WH, Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, et al. Prognostic effect of transarterial chemoembolization-induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma. Liver Transpl 2017;23:781-90.
27. Ha TY, Hwang S, Lee YJ, Kim KH, Ko GY, Gwon DI, et al. Absence of benefit of transcatheter arterial chemoembolization (TACE) in patients with resectable solitary hepatocellular carcinoma. World J Surg 2016;40:1200-10.
28. Xu W, Kwon JH, Moon YH, Kim YB, Yu YS, Lee N, et al. Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2014;140:1507-15.
29. Galizia MS, Tore HG, Chalian H, Yaghmai V. Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol 2011;18:1555-60.